Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

By morning, I was too sick to go to school. My mother took me to the doctor, and without hesitation, I lied. I told him I ...

A group of Canadian undergrads is using plants to revolutionize medicine. Faced with soaring drug prices and global shortages ...

In high doses, ivermectin can be toxic and cause central nervous system problems like blurred vision, confusion and seizures, ...

The Man Who Feels No Pain is a well-rounded action comedy with laughs, thrills, and great fight design ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo ... Much of this decline can be attributed, in my view, to investors worrying about the loss of patent ...

Entries are 100% secure and not stored in any way or shared with anyone. Period. Passwords are the bloodline of data and online security, but our research on the password habits in the U.S. shows that ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...